



Pfizer Limited

The Capital, 1802 / 1901,
Plot No. C - 70, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

March 1, 2018

The Corporate Relationship Dept.
BSE Limited
1st Floor, P.J.Towers
Dalal Street, Fort
Mumbai - 400 001
Scrip Code: 500680

The Manager, Listing Dept.
The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051
Scrip Symbol: PFIZER

Dear Sirs,

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We refer to our communication dated October 11, 2017, wherein we have informed the Stock Exchanges about the Press Release issued by Pfizer Inc., USA about its decision to review strategic alternatives for its global Consumer Healthcare business.

We wish to inform you that Pfizer Inc. has now informed the Board of Directors of the Company that they have identified certain products outside its consumer healthcare business in India, viz., Becosules, Corex and Gelusil, to be included in scope of the aforementioned review of strategic alternatives for its global Consumer Healthcare business, which has been noted by the Board of Directors of the Company.

These products have been identified for inclusion in the review since they fit well within the Pfizer Consumer Healthcare (PCH) product portfolio. Regardless of this review, Pfizer Limited will continue to focus on and build upon its core prescription portfolio through current and future investments.

Pfizer Inc. has also informed the Board of the Company that no decision has yet been made with respect to any strategic alternatives for the global Consumer Healthcare business and that Pfizer Inc. is currently in the Strategy and Readiness phase of internal evaluation of the relevant business and of considering possible strategic alternatives.

CIN : L24231MH1950PLC008311

✉ contactus.india@pfizer.com


🌐 www.pfizerindia.com

As already communicated, these alternatives could include a decision which may ultimately result in a full or partial separation of the aforementioned business from Pfizer Inc. or a decision to ultimately retain the said business. Further, until the outcome of this review of strategic alternatives is determined, there will be no change in the status of these products.

This is for your information and dissemination please.

Thanking you,

Yours truly,
For Pfizer Limited

A handwritten signature in black ink, appearing to read 'Prajeet Nair', written over a horizontal line.

Prajeet Nair
Company Secretary